Phase II Study of Nitric Oxide Donor for Men With Increasing Prostate-specific Antigen Level After Surgery or Radiotherapy for Prostate Cancer

Urology

Volumn 74, Issue 4, 2009, Pages 878-883

  Siemens, D Robert ^a   Heaton, Jeremy P W ^a   Adams, Michael A ^a   Kawakami, Jun ^a   Graham, Charles H ^a  

^a QUEEN S UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCERYL TRINITRATE; NITRIC OXIDE; NITRIC OXIDE DONOR; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CANCER SURGERY; CARCINOGENESIS; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG SAFETY; HUMAN; LOW DRUG DOSE; MALE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; SLOW DRUG RELEASE;

AGED; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NITRIC OXIDE DONORS; NITROGLYCERIN; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 70349466391     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2009.03.004     Document Type: Article

References (28)

1. Jemal A., Murray T., Ward E., et al. Cancer statistics, 2005. CA Cancer J Clin 55 (2005) 10-30
2. Han M., Partin A.W., Zahurak M., et al. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol 169 (2003) 517-523
3. Zincke H., Oesterling J.E., Blute M.L., et al. Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer. J Urol 152 (1994) 1850-1857
4. Shipley W.U., Thames H.D., Sandler H.M., et al. Radiation therapy for clinically localized prostate cancer: a multi-institutional pooled analysis. JAMA 281 (1999) 1598-1604
5. Vaupel P., Kelleher D.K., and Hockel M. Oxygen status of malignant tumors: pathogenesis of hypoxia and significance for tumor therapy. Semin Oncol 28 2 suppl 8 (2001) 29-35
6. Movsas B., Chapman J.D., Greenberg R.E., et al. Increasing levels of hypoxia in prostate carcinoma correlate significantly with increasing clinical stage and patient age: an Eppendorf pO(2) study. Cancer 89 (2000) 2018-2024
7. Postovit L.M., Adams M.A., Lash G.E., et al. Oxygen-mediated regulation of tumor cell invasiveness: involvement of a nitric oxide signaling pathway. J Biol Chem 277 (2002) 35730-35737
8. Postovit L.M., Adams M.A., Lash G.E., et al. Nitric oxide-mediated regulation of hypoxia-induced B16F10 melanoma metastasis. Int J Cancer 108 (2004) 47-53
9. Fink T., Ebbesen P., Koppelhus U., et al. Natural killer cell-mediated basal and interferon-enhanced cytotoxicity against liver cancer cells is significantly impaired under in vivo oxygen conditions. Scand J Immunol 58 (2003) 607-612
10. Siemens D.R., Hu N., Sheikhi A.K., et al. Hypoxia increases tumor cell shedding of MHC class I chain-related molecule: role of nitric oxide. Cancer Res 68 (2008) 4746-4753
11. Gatenby R.A., Kessler H.B., Rosenblum J.S., et al. Oxygen distribution in squamous cell carcinoma metastases and its relationship to outcome of radiation therapy. Int J Radiat Oncol Biol Phys 14 (1988) 831-838
12. Nordsmark M., Overgaard M., and Overgaard J. Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiother Oncol 41 (1996) 31-39
13. Frederiksen L.J., Siemens D.R., Heaton J.P., et al. Hypoxia induced resistance to doxorubicin in prostate cancer cells is inhibited by low concentrations of glyceryl trinitrate. J Urol 170 (2003) 1003-1007
14. Matthews N.E., Adams M.A., Maxwell L.R., et al. Nitric oxide-mediated regulation of chemosensitivity in cancer cells. J Natl Cancer Inst 93 (2001) 1879-1885
15. Bell E.N., Tse M.Y., Frederiksen L.J., et al. Atrial natriuretic peptide attenuates hypoxia induced chemoresistance in prostate cancer cells. J Urol 177 (2007) 751-756
16. Frederiksen L.J., Sullivan R., Maxwell L.R., et al. Chemosensitization of cancer in vitro and in vivo by nitric oxide signaling. Clin Cancer Res 13 (2007) 2199-2206
17. Pound C.R., Partin A.W., Eisenberger M.A., et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281 (1999) 1591-1597
18. Jadeski L.C., Hum K.O., Chakraborty C., et al. Nitric oxide promotes murine mammary tumour growth and metastasis by stimulating tumour cell migration, invasiveness and angiogenesis. Int J Cancer 86 (2000) 30-39
19. Xie K., Dong Z., and Fidler I.J. Activation of nitric oxide synthase gene for inhibition of cancer metastasis. J Leukoc Biol 59 (1996) 797-803
20. Rigas B., and Williams J.L. NO-releasing NSAIDs and colon cancer chemoprevention: a promising novel approach (review). Int J Oncol 20 (2002) 885-890
21. Goluboff E.T., Prager D., Rukstalis D., et al. Safety and efficacy of exisulind for treatment of recurrent prostate cancer after radical prostatectomy. J Urol 166 (2001) 882-886
22. Yasuda H., Yamaya M., Nakayama K., et al. Randomized phase II trial comparing nitroglycerin plus vinorelbine and cisplatin with vinorelbine and cisplatin alone in previously untreated stage IIIB/IV non-small-cell lung cancer. J Clin Oncol 24 (2006) 688-694
23. Patel A., Dorey F., Franklin J., et al. Recurrence patterns after radical retropubic prostatectomy: clinical usefulness of prostate specific antigen doubling times and log slope prostate specific antigen. J Urol 158 (1997) 1441-1445
24. Freedland S.J., Humphreys E.B., Mangold L.A., et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 294 (2005) 433-439
25. Mueller E., Smith M., Sarraf P., et al. Effects of ligand activation of peroxisome proliferator-activated receptor gamma in human prostate cancer. Proc Natl Acad Sci USA 97 (2000) 10990-10995
26. Rini B.I., Weinberg V., and Bok R. Prostate-specific antigen kinetics as a measure of the biologic effect of granulocyte-macrophage colony-stimulating factor in patients with serologic progression of prostate cancer. J Clin Oncol 21 (2003) 99-105
27. Beer T.M., Lemmon D., Lowe B.A., et al. High-dose weekly oral calcitriol in patients with a rising PSA after prostatectomy or radiation for prostate carcinoma. Cancer 97 (2003) 1217-1224
28. Smith M.R., Manola J., Kaufman D.S., et al. Rosiglitazone versus placebo for men with prostate carcinoma and a rising serum prostate-specific antigen level after radical prostatectomy and/or radiation therapy. Cancer 101 (2004) 1569-1574